参考文献/References:
[1]李永青. 低危非瓣膜性房颤患者发生血栓栓塞事件的影响因素分析[D]. 广州医科大学,2020.
[2]Hijazi Z,Lindb?ck J,Alexander JH,et al. The ABC(age,biomarkers,clinical history) stroke risk score:a biomarker-based risk score for predicting stroke in atrial fibrillation[J].?Eur Heart J,2016,37(20):1582-1590.
[3]Dalgaard F,Pieper K,Verheugt F,et al. GARFIELD-AF model for prediction of stroke and major bleeding in atrial fibrillation:a Danish nationwide validation study[J].?BMJ Open,2019,9(11):e033283.
[4]Halperin LF,Lee MK,Liew J,et al. Anticoagulation for patients with atrial fibrillation and end stage renal disease on dialysis:a national survey[J]. Can J Cardiol,2021,37(6):924-928.
[5]Go AS,Fang MC,Udaltsova N,et al. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation:the anticoagulation and risk factors in atrial fibrillation(ATRIA) study[J].?Circulation,2009,19(10):1363-1369.
[6]Bautista J,Bella A,Chaudhari A,et al. Advanced chronic kidney disease in non-valvular atrial fibrillation:extending the utility of R2CHADS2 to patients with advanced renal failure [J].?Clin Kidney J,2015,8(2):226-231.
[7] Avgil Tsadok M,Berliner Senderey A,Reges O,et al. Comparison of stroke risk stratification scores for atrial fibrillation[J].?Am J Cardiol,2019,123(11):1828-1834.
[8]Maheshwari A,Norby FL,Roetker NS,et al. Refining prediction of atrial fibrillation-related stroke using the P2-CHA2DS2-VASc score[J]. Circulation,2019,139(2):180-191.
[9]Aspberg S,Chang Y,Atterman A,et al. Comparison of the ATRIA,CHADS2,and CHA2DS2-VASc stroke risk scores in predicting ischaemic stroke in a large Swedish cohort of patients with atrial fibrillation[J].?Eur Heart J,2016,37(42):3203-3210.
[10]Tada H,Shiffman D,Smith JG,et al. Twelve-single nucleotide polymorphism genetic risk score identifies individuals at increased risk for future atrial fibrillation and stroke[J].?Stroke,2014,45(10):2856-2862.
[11]金慧,张振刚,袁晓晨. 非瓣膜性心房颤动卒中风险评估研究进展[J]. 国际心血管病杂志,2019,46(6):324-327.
[12]Glotzer TV,Daoud EG,Wyse DG,et al. The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk:the TRENDS study[J].?Circ Arrhythm Electrophysiol,2009,2(5):474-480.
[13]Israel CW,Gr?nefeld G,Ehrlich JR,et al. Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device:implications for optimal patient care[J].?J Am Coll Cardiol,2004,43(1):47-52.
[14]Ogata T,Matsuo R,Kiyuna F,et al. Left atrial size and long-term risk of recurrent stroke after acute ischemic stroke in patients with nonvalvular atrial fibrillation[J].?J Am Heart Assoc,2017,6(8):e006402.
[15]Broughton ST,O’Neal WT,Salahuddin T,et al. The influence of left atrial enlargement on the relationship between atrial fibrillation and stroke[J].?J Stroke Cerebrovasc Dis,2016,25(6):1396-1402.
[16]Lai CL,Chien KL,Hsu HC,et al. Left atrial dimension and risk of stroke in women without atrial fibrillation:the Chin-Shan Community Cardiovascular Cohort study[J].?Echocardiography,2011,28(10):1054-1060.
[17]孙艺红,胡大一. 非瓣膜病心房颤动患者全球抗凝注册研究中国亚组基线数据分析[J]. 中华心血管病杂志,2014,42(10):846-850.
[18]国家卫生健康委员会脑卒中防治专家委员会房颤卒中防治专业委员会,中华医学会心电生理和起搏分会,中国医师协会心律学专业委员会. 中国心源性卒中防治指南(2019)[J]. 中华心律失常学杂志,2019,23(6):463-484.
[19]杨英,扶泽南,杨龙,等. 左心耳结构复杂性与非瓣膜性心房颤动患者左心耳血栓形成的关系[J]. 中国循环杂志,2020,35(3):277-281.
[20]Yamamoto M,Seo Y,Kawamatsu N,et al. Complex left atrial appendage morphology and left atrial appendage thrombus formation in patients with atrial fibrillation[J].?Circ Cardiovasc Imaging,2014,7(2):337-343.
[21]Healey JS,Alings M,Ha A,et al. Subclinical atrial fibrillation in older patients[J].?Circulation,2017,136(14):1276-1283.
[22]Verma A,Cairns JA,Mitchell LB,et al. 2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation[J].?Can J Cardiol,2014,30(10):1114-1130.
[23]Kirchhof P,Benussi S,Kotecha D,et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS[J].?Eur Heart J,2016,37(38):2893-2962.
[24]Hart RG,Pearce LA,Miller VT,et al. Cardioembolic vs. noncardioembolic strokes in atrial fibrillation:frequency and effect of antithrombotic agents in the stroke prevention in atrial fibrillation studies[J].?Cerebrovasc Dis,2000,10(1):39-43.
[25]Jia B,Lynn HS,Rong F,et al. Meta-analysis of efficacy and safety of the new anticoagulants versus warfarin in patients with atrial fibrillation[J].?J Cardiovasc Pharmacol,2014,64(4):368-374.
[26]Eikelboom JW,Connolly SJ,Bosch J,et al. Rivaroxaban with or without aspirin in stable cardiovascular disease[J].?N Engl J Med,2017,377(14):1319-1330.
相似文献/References:
[1]贺鹏康,周菁.心房颤动治疗新技术——冷冻球囊消融[J].心血管病学进展,2016,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
HE Pengkang,ZHOU Jing.Cryoballoon Ablation, A Novel Technology for Atrial Fibrillation Treatment[J].Advances in Cardiovascular Diseases,2016,(11):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
[2]都明辉,施海峰*,佟佳宾,等.心房颤动消融相关性无症状性脑缺血[J].心血管病学进展,2016,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
DU Minghui,SHI Haifeng*,TONG Jiabin,et al.Silent Cerebral Ischemia Related to Atrial Fibrillation Ablation[J].Advances in Cardiovascular Diseases,2016,(11):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
[3]郑环杰,综述,肖骅,等.心房颤动抗栓治疗研究进展[J].心血管病学进展,2016,(2):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
ZHENG Huanjie,XIAO Hua.Progress of Antithrombotic Therapy in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(11):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
[4]张清,综述,罗素新,等.新型Xa 因子抑制剂———依度沙班在心房颤动患者抗凝治疗中的研究进展[J].心血管病学进展,2016,(2):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
ZHANG Qing,LUO Suxin,TANG Jiong.Novel Factor Xa Inhibitors—Edoxaban in Prevention of Stroke in
Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(11):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
[5]胡红玲,综述,罗素新,等.预防非瓣膜性心房颤动性脑卒中的治疗新进展[J].心血管病学进展,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
HU Hongling,LUO Suxin.New Progress in the Treatment for Cerebral Apoplexy of Nonvalvular
Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(11):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
[6]王超,杨国澍,综述,等.关附甲素治疗心房颤动的研究进展[J].心血管病学进展,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
WANG Chao,YANG Guoshu,CAI Lin,et al.Research Progress of the Treatment of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(11):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
[7]徐小东,综述,杨东辉,等.决奈达隆治疗心房颤动的现状及展望[J].心血管病学进展,2016,(4):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
XU Xiaodong,YANG Donghui.Status and Prospect of Dronedarone in Treating Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(11):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
[8]张莎,储国俊,吴弘.经导管左心耳封堵术的临床应用进展[J].心血管病学进展,2015,(5):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
ZHANG Sha,CHU Guojun,WU Hong.Clinial Application Advances in Left Atrial Appendage Closure[J].Advances in Cardiovascular Diseases,2015,(11):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
[9]汪俊,杨浩.心房颤动射频消融的术式演变[J].心血管病学进展,2015,(5):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
WANG Jun,YANG Hao.Evolution of Radiofrequency Ablation of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(11):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
[10]赵璐,苏立.心房颤动与离子通道重构研究进展[J].心血管病学进展,2015,(5):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
ZHAO Lu,SU Li.Research Progress of Atrial Fibrillation and Ion Channel Remodeling[J].Advances in Cardiovascular Diseases,2015,(11):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
[11]夏熠 刘飞 夏云龙.糖尿病合并心房颤动的相关研究进展[J].心血管病学进展,2020,(1):27.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.008]
XIA YiLIU FeiXIA Yunlong.Research Progress in Diabetes Mellitus Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2020,(11):27.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.008]
[12]白金龙 李洪仕 蔡衡.非瓣膜性心房颤动导管消融术后抗凝策略的研究进展[J].心血管病学进展,2021,(1):30.[doi:10.16806/j.cnki.issn.1004-3934.201.01.000]
[13]董皓宇 杨乙珩 夏云龙.心房颤动的抗凝治疗：CHA2DS2-VASc评分之外[J].心血管病学进展,2022,(5):403.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.005]
Beyond CHADS-VASc Score.Anticoagulant Therapy for Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2022,(11):403.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.005]
[14]加依娜·加尔肯 汤宝鹏 周贤惠 李耀东 芦颜美.非瓣膜性心房颤动患者“一站式”手术策略的有效性和安全性:单中心经验[J].心血管病学进展,2022,(12):1141.[doi:10.16806/j.cnki.issn.1004-3934.2022.12.019]
Jiayina Jiaerken,TANG Baopeng,ZHOU Xianhui,et al.Effectiveness and Safety of "One-Step" Procedure in Patients with Non-Valvular Atrial Fibrillation:A Single Center Experience?/html>[J].Advances in Cardiovascular Diseases,2022,(11):1141.[doi:10.16806/j.cnki.issn.1004-3934.2022.12.019]
[15]陈建福 陈灿.血压目标范围内时间与心血管疾病关系的研究进展[J].心血管病学进展,2024,(7):617.[doi:10.16806/j.cnki.issn.1004-3934.2024.07.010]
CHEN Jianfu,CHEN Can.The Relationship Between Time in Target Range and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2024,(11):617.[doi:10.16806/j.cnki.issn.1004-3934.2024.07.010]